Moleculin Biotech CS (MBRX) Stock Price, Quote & News

Company Profile

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to...

Industry: Biotechnology

Sector: Healthcare

Phone: (713) 300-5160

Website: moleculin.com

Address:

5300 Memorial Drive, Suite 950, Houston, United States

jim64 Aug. 25 at 1:15 PM

$MBRX This company’s biggest problem is management. Until they clean house you’re wasting your time and money. Just go back years and check it out. It’s all there for everyone to see if you’re interested.

0 · Reply

CrisMars Aug. 25 at 12:19 AM

$MBRX …a JV with a first line anthracycline drug company is a good move…

1 · Reply

CrisMars Aug. 24 at 11:00 PM

$MBRX is poised for a run…news coming every week…

0 · Reply

baliba Aug. 24 at 12:22 PM

$MBRX i added like insider

0 · Reply

jkgyuool Aug. 23 at 10:08 PM

$MBRX sure you did

0 · Reply

MGeronimo Aug. 23 at 9:23 PM

$MBRX ADDED AT .57

0 · Reply

Love_To_Learn Aug. 22 at 7:38 PM

hmmnow now will ahev deviations deal with this later due to dblt mspr vcig thing $MBRX sit tight!

0 · Reply

jkgyuool Aug. 22 at 2:18 PM

$MBRX all games and manipulation

0 · Reply

kolococo Aug. 22 at 12:48 AM

$MBRX follow the smart money

1 · Reply

Robcfg Aug. 21 at 9:58 PM

$QMMM $IXHL $MBRX starting to look good $CRDL on the radar too.

0 · Reply

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 13, 2025, 8:05 AM EDT - 12 days ago

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

Aug 6, 2025, 8:40 AM EDT - 19 days ago

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

Jul 30, 2025, 8:35 AM EDT - 26 days ago

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

Jul 22, 2025, 8:45 AM EDT - 4 weeks ago

Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 17, 2025, 8:25 AM EDT - 5 weeks ago

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

Jul 9, 2025, 8:35 AM EDT - 6 weeks ago

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Jun 26, 2025, 8:15 AM EDT - 2 months ago

Top 3 Health Care Stocks You'll Regret Missing This Quarter

CPRX

Jun 20, 2025, 9:20 AM EDT - 2 months ago

Moleculin Announces $5.9 Million Public Offering

Jun 18, 2025, 7:45 AM EDT - 2 months ago

Moleculin Participates in Virtual Investor “What This Means” Segment

Jun 18, 2025, 7:30 AM EDT - 2 months ago

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Jun 5, 2025, 8:00 AM EDT - 2 months ago

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Jun 4, 2025, 8:45 AM EDT - 2 months ago

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

May 14, 2025, 12:20 PM EDT - 3 months ago

Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:30 AM EDT - 3 months ago

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 8:40 AM EDT - 3 months ago

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

May 7, 2025, 9:00 AM EDT - 3 months ago

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

May 6, 2025, 9:00 AM EDT - 3 months ago

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

May 5, 2025, 8:45 AM EDT - 4 months ago

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

Apr 29, 2025, 8:35 AM EDT - 4 months ago

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

Apr 17, 2025, 8:30 AM EDT - 4 months ago

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 1, 2025, 8:30 AM EDT - 5 months ago

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Mar 24, 2025, 10:50 AM EDT - 5 months ago

Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript

Mar 24, 2025, 7:05 AM EDT - 5 months ago

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 19, 2025, 8:05 AM EDT - 5 months ago

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Mar 11, 2025, 8:45 AM EDT - 5 months ago

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Mar 10, 2025, 8:45 AM EDT - 6 months ago

Moleculin to Present at the 37th Annual ROTH Conference

Mar 6, 2025, 8:30 AM EST - 6 months ago

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

Mar 3, 2025, 8:30 AM EST - 6 months ago

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

Feb 25, 2025, 12:35 PM EST - 6 months ago

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Feb 13, 2025, 1:19 PM EST - 6 months ago

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

Feb 13, 2025, 1:05 PM EST - 6 months ago

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Feb 13, 2025, 9:25 AM EST - 6 months ago

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Feb 11, 2025, 8:40 AM EST - 6 months ago

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Jan 27, 2025, 8:30 AM EST - 7 months ago

Moleculin Participates in Virtual Investor "What This Means" Segment

Jan 8, 2025, 8:30 AM EST - 8 months ago

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026

Dec 11, 2024, 8:00 AM EST - 9 months ago

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

Nov 18, 2024, 8:15 AM EST - 10 months ago

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

Nov 14, 2024, 8:15 AM EST - 10 months ago

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Nov 12, 2024, 8:00 AM EST - 10 months ago

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

Nov 11, 2024, 11:17 AM EST - 10 months ago

Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 7:05 AM EST - 10 months ago

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 9:00 AM EST - 10 months ago

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

Nov 4, 2024, 8:30 AM EST - 10 months ago

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

Oct 17, 2024, 8:40 AM EDT - 11 months ago

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available

Oct 7, 2024, 8:30 AM EDT - 11 months ago

Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024

Oct 4, 2024, 9:00 AM EDT - 11 months ago

Moleculin to Present at Two Upcoming Investor Conferences

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Moleculin Participates in Virtual Investor "What this Means" Segment

Sep 9, 2024, 8:15 AM EDT - 1 year ago

Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma

jim64 Aug. 25 at 1:15 PM

0 · Reply

CrisMars Aug. 25 at 12:19 AM

$MBRX …a JV with a first line anthracycline drug company is a good move…

1 · Reply

CrisMars Aug. 24 at 11:00 PM

$MBRX is poised for a run…news coming every week…

0 · Reply

baliba Aug. 24 at 12:22 PM

$MBRX i added like insider

0 · Reply

jkgyuool Aug. 23 at 10:08 PM

$MBRX sure you did

0 · Reply

MGeronimo Aug. 23 at 9:23 PM

$MBRX ADDED AT .57

0 · Reply

Love_To_Learn Aug. 22 at 7:38 PM

hmmnow now will ahev deviations deal with this later due to dblt mspr vcig thing $MBRX sit tight!

0 · Reply

jkgyuool Aug. 22 at 2:18 PM

$MBRX all games and manipulation

0 · Reply

kolococo Aug. 22 at 12:48 AM

$MBRX follow the smart money

1 · Reply

Robcfg Aug. 21 at 9:58 PM

$QMMM $IXHL $MBRX starting to look good $CRDL on the radar too.

0 · Reply

Robcfg Aug. 21 at 6:15 PM

$MBRX

0 · Reply

DARKP00L Aug. 21 at 2:20 PM

$MBRX the market is buzzing about this stock. Expect possible price changes!

1 · Reply

Hihidudu Aug. 21 at 3:17 AM

$MBRX actually this stock just needs 1 good news to fly, its been up and down for a while but always bounced back

1 · Reply

Zdxss1 Aug. 20 at 4:26 PM

$MBRX I am an investor in this company and I defend my investments and money and it is normal for me to be here. What are you doing here and why are you hiding behind another person and using more than one pseudonym تري انت انكشفت عيب عليك خلي وجهك ذرة ماء

1 · Reply

cheeseandsmile Aug. 20 at 4:06 PM

$MBRX 🚨 paid stock promoter 🚨 I guess from JTC Team office

0 · Reply

Zdxss1 Aug. 20 at 3:50 PM

$MBRX This person is an Arab in disguise. He has lost almost all his money. He claims that he is smart and that people are stupid. He is mentally ill. He is happy when he sees people sad and sad when people are happy. A dog is better than them.

0 · Reply

jkgyuool Aug. 20 at 2:38 PM

$MBRX I guess this is how much shareholders are valued. Thanks leadership

0 · Reply

cheeseandsmile Aug. 20 at 1:46 PM

$MBRX huge dump is coming

0 · Reply